Evolent Health, Inc. (NYSE:EVH) Shares Sold by ERn Financial LLC

ERn Financial LLC reduced its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 50.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 29,574 shares of the technology company's stock after selling 30,000 shares during the quarter. ERn Financial LLC's holdings in Evolent Health were worth $836,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EVH. NBC Securities Inc. boosted its holdings in shares of Evolent Health by 16.6% during the 1st quarter. NBC Securities Inc. now owns 2,461 shares of the technology company's stock worth $81,000 after purchasing an additional 350 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Evolent Health by 3.2% during the second quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company's stock worth $298,000 after buying an additional 480 shares during the last quarter. Ascent Group LLC grew its holdings in Evolent Health by 2.8% in the 1st quarter. Ascent Group LLC now owns 20,330 shares of the technology company's stock valued at $667,000 after buying an additional 550 shares in the last quarter. SeaCrest Wealth Management LLC raised its holdings in shares of Evolent Health by 6.3% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company's stock worth $195,000 after acquiring an additional 600 shares during the period. Finally, American International Group Inc. boosted its position in shares of Evolent Health by 1.2% during the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company's stock valued at $1,817,000 after acquiring an additional 640 shares during the last quarter.

Insider Buying and Selling

In other news, COO Emily Ann Rafferty sold 8,861 shares of the firm's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the sale, the chief operating officer now directly owns 63,408 shares in the company, valued at approximately $1,902,240. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Emily Ann Rafferty sold 8,861 shares of the firm's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $265,830.00. Following the sale, the chief operating officer now owns 63,408 shares of the company's stock, valued at approximately $1,902,240. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley sold 187,904 shares of the company's stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the completion of the transaction, the chief executive officer now directly owns 411,924 shares of the company's stock, valued at $12,357,720. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 307,291 shares of company stock worth $9,290,385. Company insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Truist Financial reaffirmed a "buy" rating and set a $33.00 target price on shares of Evolent Health in a research note on Tuesday, August 27th. Royal Bank of Canada reiterated an "outperform" rating and issued a $42.00 price objective on shares of Evolent Health in a research report on Tuesday, October 8th. Stephens reissued an "overweight" rating and set a $42.00 target price on shares of Evolent Health in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their price target on Evolent Health from $36.00 to $45.00 and gave the company an "overweight" rating in a research note on Monday, August 19th. Finally, KeyCorp assumed coverage on Evolent Health in a research report on Friday, October 11th. They set an "overweight" rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $39.91.

Evolent Health Stock Up 0.5 %

Evolent Health stock traded up $0.13 during mid-day trading on Wednesday, reaching $26.52. 946,437 shares of the company's stock were exchanged, compared to its average volume of 1,605,402. The company has a fifty day moving average of $28.74 and a 200-day moving average of $25.69. The company has a market cap of $3.08 billion, a P/E ratio of -21.22 and a beta of 1.56. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a twelve month low of $17.98 and a twelve month high of $35.00.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, August 8th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.09. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The firm had revenue of $647.10 million during the quarter, compared to analyst estimates of $636.46 million. During the same period last year, the business posted $0.06 earnings per share. Evolent Health's revenue was up 37.9% compared to the same quarter last year. Sell-side analysts expect that Evolent Health, Inc. will post 0.86 EPS for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.